Recruiting
Phase 1
Phase 2

Venetoclax and Lintuzumab-Ac225 in AML Patients

Sponsor:

Actinium Pharmaceuticals

Code:

NCT03867682

Conditions

Acute Myeloid Leukemia

Relapsed Adult AML

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Lintuzumab-Ac225

Venetoclax

Spironolactone

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information